Reference is made to the stock exchange announcement from Salmon Evolution ASA
("Salmon Evolution" or the "Company", OSE: SALME) on 29 April 2023 regarding
increased mortality levels in selected fish groups.
The Company has taken a number of actions to mitigate the negative effects of
the situation. Harvesting of batch 2 started last week and two out of four tanks
have now been harvested out, yielding about 310 tonnes HOG. The harvest
confirmed strong product quality, evidenced by a superior grade share of more
than 90%. The fish has subsequently been sold at attractive prices. The last two
tanks containing batch 2 will be fully harvested out this week, about one month
ahead of the original plan.
The Company continues to see elevated mortality levels for one of the subgroups
in each of batch 3 and 4, but the situation has stabilized somewhat over the
last week. Batch 5 continues to see low mortality levels and normal feeding.
The investigation into the root cause for the increased mortality levels
continue, but the Company has strong indications that AGD is the triggering
cause. AGD is a common challenge for the conventional salmon farming industry
and there are well proven treatment methods, namely by using freshwater. The
Company has therefore secured relevant capacities and plans to start freshwater
treatment this week with the aim of normalizing the situation and thereby
avoiding early harvest of the affected subgroups in batch 3 and 4.
In parallel, the Company is implementing measures to minimize the risk of such
problem in the first place, including but not limited to applying a
substantially higher UV disinfection dose and enhanced cleaning and disinfection
of emptied tanks and connected systems.
The Company's stocking plan for new batches remains unchanged with two new
batches planned stocked during the second quarter and another three batches
during the second half of 2023.
For further information, contact:
Trond Håkon Schaug-Pettersen
CEO, Salmon Evolution
+47 911 91 327
Menu